7D2A Stock Overview
A medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sedana Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.06 |
| 52 Week High | SEK 2.42 |
| 52 Week Low | SEK 1.16 |
| Beta | 0.26 |
| 11 Month Change | 8.04% |
| 3 Month Change | 54.63% |
| 1 Year Change | -8.42% |
| 33 Year Change | -71.06% |
| 5 Year Change | -26.87% |
| Change since IPO | 4.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7D2A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.4% | 1.4% | 0.8% |
| 1Y | -8.4% | -1.1% | 2.0% |
Return vs Industry: 7D2A underperformed the German Medical Equipment industry which returned 4.1% over the past year.
Return vs Market: 7D2A underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 7D2A volatility | |
|---|---|
| 7D2A Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7D2A's share price has been volatile over the past 3 months.
Volatility Over Time: 7D2A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 83 | Johannes Doll | www.sedanamedical.com |
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; and Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care, as well as AnaConDa, a medical device enabling administration of inhaled anaesthetics. It also provides FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; Scavenging tube, a one piece pre-connected tube designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; FlurAbsorb mount to hold the FlurAbsorb during scavenging of anesthetic gas; FlurAbsorb-S mount to hold the FlurAbsorb-S during scavenging of anesthetic gas; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and Mindray exhaust connector, which enables to connect the exhaust of the ventilator to an active or passive scavenging system.
Sedana Medical AB (publ) Fundamentals Summary
| 7D2A fundamental statistics | |
|---|---|
| Market cap | €202.58m |
| Earnings (TTM) | -€2.01m |
| Revenue (TTM) | €14.53m |
13.9x
P/S Ratio-100.7x
P/E RatioIs 7D2A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7D2A income statement (TTM) | |
|---|---|
| Revenue | SEK 164.91m |
| Cost of Revenue | SEK 48.65m |
| Gross Profit | SEK 116.26m |
| Other Expenses | SEK 139.09m |
| Earnings | -SEK 22.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 70.50% |
| Net Profit Margin | -13.85% |
| Debt/Equity Ratio | 0% |
How did 7D2A perform over the long term?
See historical performance and comparison